+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-Cystic Fibrosis Bronchiectasis (NCFB) - Market Insights, Epidemiology and Market Forecast - 2030

  • ID: 4871922
  • Drug Pipelines
  • May 2020
  • Region: Global
  • 152 Pages +
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Aradigm Corporation
  • Insmed Incorporated
  • Novartis Pharmaceuticals
  • Zambon
  • MORE
This report delivers an in-depth understanding of the Non-cystic fibrosis bronchiectasis, historical and forecasted epidemiology as well as the Non-cystic fibrosis bronchiectasis market trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Non-cystic fibrosis bronchiectasis market report provides current treatment practices, emerging drugs, Non-cystic fibrosis bronchiectasis market share of the individual therapies, current and forecasted Non-cystic fibrosis bronchiectasis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Non-cystic fibrosis bronchiectasis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2030

Non-cystic fibrosis bronchiectasis (NCFB) Disease Understanding and Treatment Algorithm

Non-cystic fibrosis bronchiectasis Overview

Bronchiectasis is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree which leads to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are daily cough, daily sputum production, and frequent respiratory infections. In patients without cystic fibrosis, the condition is known as non-cystic fibrosis bronchiectasis (NCFB). Although NCFB was once a very uncommon diagnosis, in the last two decades, its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice.

Non-cystic fibrosis bronchiectasis Diagnosis

Non-cystic fibrosis bronchiectasis presents with a range of clinical manifestations from incidentally found bronchiectasis in asymptomatic individuals to massive hemoptysis and respiratory failure. With the widespread use of CT, clinicians increasingly encounter the ‘incidental' finding of bronchiectasis in asymptomatic patients who undergo chest or abdominal imaging for unrelated purposes. However, the most common clinical presentation is between these extremes.

Physical exam and history may contribute to the diagnosis of bronchiectasis.

The British Thoracic Society (BTS) guidelines for bronchiectasis suggest all patients should undergo the investigations like, baseline spirometry and peak expiratory flow rate, sputum culture and others.  

Non-cystic fibrosis bronchiectasis Treatment

It covers the details of conventional and current medical therapies available in the Non-cystic fibrosis bronchiectasis market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

The Non-cystic fibrosis bronchiectasis market report gives a thorough understanding of Non-cystic fibrosis bronchiectasis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Non-cystic fibrosis bronchiectasis treatment algorithms and treatment guidelines for Non-cystic fibrosis bronchiectasis in the US, Europe, and Japan.

Non-cystic fibrosis bronchiectasis Epidemiology

The Non-cystic fibrosis bronchiectasis epidemiology division provide the insights about historical and current Non-cystic fibrosis bronchiectasis patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Non-cystic fibrosis bronchiectasis epidemiology [segmented as Total Prevalence, Diagnosed Population, Etiology associated with NCFB, Gender-specific Prevalent Population, Severity and Microbiology of NCFB] scenario of Non-cystic fibrosis bronchiectasis in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Non-cystic fibrosis bronchiectasis Epidemiology

The epidemiology segment also provides the Non-cystic fibrosis bronchiectasis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom) and Japan.

Non-cystic fibrosis bronchiectasis Drug Chapters

Drug chapter segment of the Non-cystic fibrosis bronchiectasis report encloses the detailed analysis of Non-cystic fibrosis bronchiectasis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Non-cystic fibrosis bronchiectasis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Non-cystic fibrosis bronchiectasis Marketed Drugs

Despite the lack of medications approved by regulatory agencies for the treatment of bronchiectasis patients, various drugs and strategies have shown benefits in improving both quality of life and clinical outcomes. Since bronchiectasis is a complex and heterogeneous disease, treatment should be individualized, considering the peculiarities and clinical manifestations of each patient, and some specific conditions should be treated concurrently. However, some recommendations are important for all bronchiectasis patients, as are some interventions targeted at phenotypes specific to the disease.

Products detail in the report.

Non-cystic fibrosis bronchiectasis Emerging Drugs

Ciprofloxacin dispersion for inhalation: Aradigm Corporation

Ciprofloxacin dispersion for inhalation, also known as Apulmiq (US), Linhaliq (Europe), and Pulmaquin, is an experimental antibiotic for the treatment of non-cystic fibrosis bronchiectasis with chronic P. aeruginosa lung infection; Aradigm is developing this product. Apulmiq is an inhalable form of ciprofloxacin to treat patients who have non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa lung infection. The drug has received both Fast Track Designation and Orphan Drug Designation for the treatment of patients with non-CF BE.

Products detail in the report.

Non-cystic fibrosis bronchiectasis Market Outlook

The Non-cystic fibrosis bronchiectasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Non-cystic fibrosis bronchiectasis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of Non-cystic fibrosis bronchiectasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Non-cystic fibrosis bronchiectasis market in US is expected to increase with a CAGR of 4% during 2017-2030.

Key Findings

This section includes a glimpse of the Non-cystic fibrosis bronchiectasis market in 7MM.

The United States Market Outlook

This section provides the total Non-cystic fibrosis bronchiectasis market Size and market Size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Non-cystic fibrosis bronchiectasis market Size and market Size by therapies in Germany, France, Italy, Spain and the United Kingdom is provided in this section.

Japan Market Outlook

The total Non-cystic fibrosis bronchiectasis market Size and market Size by therapies in Japan is also mentioned.

Non-cystic fibrosis bronchiectasis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Non-cystic fibrosis bronchiectasis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Non-cystic fibrosis bronchiectasis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and Size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Non-cystic fibrosis bronchiectasis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Non-cystic fibrosis bronchiectasis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Non-cystic fibrosis bronchiectasis emerging therapies.

Reimbursement Scenario in Non-cystic fibrosis bronchiectasis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Non-cystic fibrosis bronchiectasis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Non-cystic fibrosis bronchiectasis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Non-cystic fibrosis bronchiectasis Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Non-cystic fibrosis bronchiectasis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Non-cystic fibrosis bronchiectasis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Non-cystic fibrosis bronchiectasis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Non-cystic fibrosis bronchiectasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non-cystic fibrosis bronchiectasis market
Report Highlights
  • In the coming years, Non-cystic fibrosis bronchiectasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-cystic fibrosis bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Non-cystic fibrosis bronchiectasis. Launch of emerging therapies, will significantly impact the Non-cystic fibrosis bronchiectasis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Non-cystic fibrosis bronchiectasis
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Non-cystic fibrosis bronchiectasis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Non-cystic fibrosis bronchiectasis Pipeline Analysis
  • Non-cystic fibrosis bronchiectasis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Non-cystic fibrosis bronchiectasis Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • Non-cystic fibrosis bronchiectasis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Non-cystic fibrosis bronchiectasis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Non-cystic fibrosis bronchiectasis Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Non-cystic fibrosis bronchiectasis total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Non-cystic fibrosis bronchiectasis market Size during the forecast period (2017-2030)?
  • At what CAGR, the Non-cystic fibrosis bronchiectasis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Non-cystic fibrosis bronchiectasis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Non-cystic fibrosis bronchiectasis market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the Non-cystic fibrosis bronchiectasis?
  • What is the historical Non-cystic fibrosis bronchiectasis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Non-cystic fibrosis bronchiectasis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-cystic fibrosis bronchiectasis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Non-cystic fibrosis bronchiectasis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the treatment of Non-cystic fibrosis bronchiectasis along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Non-cystic fibrosis bronchiectasis (NCFB) in USA, Europe and Japan?
  • What is the Non-cystic fibrosis bronchiectasis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy etc.?
  • How many companies are developing therapies for the treatment of Non-cystic fibrosis bronchiectasis?
  • How many therapies are developed by each company for the treatment of Non-cystic fibrosis bronchiectasis?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Non-cystic fibrosis bronchiectasis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non-cystic fibrosis bronchiectasis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Non-cystic fibrosis bronchiectasis and their status?
  • What are the key designations that have been granted for the emerging therapies for Non-cystic fibrosis bronchiectasis?
  • What are the global historical and forecasted market of Non-cystic fibrosis bronchiectasis?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Non-cystic fibrosis bronchiectasis market
  • To understand the future market competition in the Non-cystic fibrosis bronchiectasis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Non-cystic fibrosis bronchiectasis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Non-cystic fibrosis bronchiectasis market
  • To understand the future market competition in the Non-cystic fibrosis bronchiectasis market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aradigm Corporation
  • Insmed Incorporated
  • Novartis Pharmaceuticals
  • Zambon
  • MORE
1. Key Insights

2. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance
2.1. Market Share (%) Distribution of NCFB in 2017
2.2. Market Share (%) Distribution of NCFB in 2030

3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and manifestations
3.3. Symptoms
3.4. Pathophysiology
3.5. Diagnosis
3.6. Prognosis

4. Treatment and management

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Total Prevalence of Non-cystic Fibrosis Bronchiectasis in 7MM

6. Country Wise-Epidemiology
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Prevalence of Non-cystic fibrosis bronchiectasis
6.1.3. Diagnose prevalence of NCFB in United States
6.1.4. Gender Specific Diagnosed prevalence NCFB in United States
6.1.5. Severity Specific Diagnosed prevalence NCFB in United States
6.1.6. Etiology associated with NCFB in United States
6.1.7. Microbiology of NCFB patients in United States
6.2. EU-5
6.2.1. Assumptions and Rationale
6.2.2. Germany
6.2.2.1. Prevalence of Non-cystic fibrosis bronchiectasis
6.2.2.2. Diagnose prevalence of NCFB in Germany
6.2.2.3. Gender Specific Diagnosed prevalence NCFB in Germany
6.2.2.4. Severity Specific Diagnosed prevalence NCFB in Germany
6.2.2.5. Etiology associated with NCFB in Germany
6.2.2.6. Microbiology of NCFB patients in Germany
6.2.3. France
6.2.3.1. Prevalence of Non-cystic fibrosis bronchiectasis in France
6.2.3.2. Diagnose prevalence of NCFB in France
6.2.3.3. Gender Specific Diagnosed prevalence NCFB in France
6.2.3.4. Severity Specific Diagnosed prevalence NCFB in France
6.2.3.5. Etiology associated with NCFB in France
6.2.3.6. Microbiology of NCFB patients in France
6.2.4. Italy
6.2.4.1. Prevalence of Non-cystic fibrosis bronchiectasis in Italy
6.2.4.2. Diagnose prevalence of NCFB in Italy
6.2.4.3. Gender Specific Diagnosed prevalence NCFB in Italy
6.2.4.4. Severity Specific Diagnosed prevalence NCFB in Italy
6.2.4.5. Etiology associated with NCFB in Italy
6.2.4.6. Microbiology of NCFB patients in Italy
6.2.5. Spain
6.2.5.1. Prevalence of Non-cystic fibrosis bronchiectasis in Spain
6.2.5.2. Diagnose prevalence of NCFB in Spain
6.2.5.3. Gender Specific Diagnosed prevalence NCFB in Spain
6.2.5.4. Severity Specific Diagnosed prevalence NCFB in Spain
6.2.5.5. Etiology associated with NCFB in Spain
6.2.5.6. Microbiology of NCFB patients in Spain
6.2.6. United Kingdom
6.2.6.1. Prevalence of Non-cystic fibrosis bronchiectasis in the UK
6.2.6.2. Diagnose prevalence of NCFB in the UK
6.2.6.3. Gender Specific Diagnosed prevalence NCFB in UK
6.2.6.4. Severity Specific Diagnosed prevalence NCFB in UK
6.2.6.5. Etiology associated with NCFB in UK
6.2.6.6. Microbiology of NCFB patients in UK
6.3. Japan
6.3.1. Assumptions and Rationale
6.3.2. Prevalence of Non-cystic fibrosis bronchiectasis in Japan
6.3.3. Diagnose prevalence of NCFB in Japan
6.3.4. Gender Specific Diagnosed prevalence NCFB in Japan
6.3.5. Severity Specific Diagnosed prevalence NCFB in Japan
6.3.6. Etiology associated with NCFB in Japan
6.3.7. Microbiology of NCFB patients in Japan

7. Unmet needs

8. Emerging Drugs
8.1. Ciprofloxacin dispersion for inhalation: Aradigm Corporation
8.1.1. Product Description
8.1.2. Product Development Activities
8.1.3. Clinical development
8.1.4. Clinical Trials Information
8.1.5. Safety and Efficacy
8.1.6. Product Profile
8.2. Colistimethate sodium: Zambon
8.2.1. Product Description
8.2.2. Product Development Activities
8.2.3. Clinical development
8.2.4. Clinical Trials Information
8.2.5. Product Profile
8.3. Tobramycin inhalation powder (TIP): Novartis Pharmaceuticals
8.3.1. Product Description
8.3.2. Product Development Activities
8.3.3. Clinical development
8.3.4. Clinical Trials Information
8.3.5. Product Profile
8.4. INS1007: Insmed Incorporated
8.4.1. Product Description
8.4.2. Other Development Activities
8.4.3. Clinical Development
8.4.4. Clinical Trials Information
8.4.5. Safety and Efficacy
8.4.6. Product Profile

9. Market Outlook by Country
9.1. Key Findings
9.2. Market size of Non-cystic Fibrosis Bronchiectasis in 7MM
9.3. The United States: Market Outlook
9.4. United States Market Size
9.4.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.4.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
9.5. EU-5 Countries: Market Outlook
9.5.1. Germany Market Size
9.5.1.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.5.1.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
9.5.2. France Market Size
9.5.2.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.5.2.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
9.5.3. Spain Market Size
9.5.3.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.5.3.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
9.5.4. Italy Market Size
9.5.4.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.5.4.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
9.5.5. United Kingdom Market Size
9.5.5.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.5.5.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
9.6. Japan: Market Outlook
9.6.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
9.6.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy

10. Market Drivers

11. Market Barriers

12. Appendix
12.1. Report Methodology

13. Publisher Capabilities

14. Disclaimer

15. About the Publisher

List of Tables
Table 1: Conditions associated with the development of bronchiectasis
Table 2: Total Prevalent Population of NCFB in 7MM (2017-2030)
Table 3: Prevalent Population of NCFB in the United States (2017-2030)
Table 4: Diagnosed Prevalent Population of NCFB in the United States (2017-2030)
Table 5: Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
Table 6: Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
Table 7: Etiology associated with NCFB in the United States (2017-2030)
Table 8: Microbiology of NCFB patients in the United States (2017-2030)
Table 9: Prevalent Population of NCFB in the Germany (2017-2030)
Table 10: Diagnosed Prevalent Population of NCFB in Germany (2017-2030)
Table 11: Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
Table 12: Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
Table 13: Etiology associated with NCFB in the Germany (2017-2030)
Table 14: Microbiology of NCFB patients in Germany (2017-2030)
Table 15: Prevalent Population of NCFB in France (2017-2030)
Table 16: Diagnosed Prevalent Population of NCFB in France (2017-2030)
Table 17: Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
Table 18: Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
Table 19: Etiology associated with NCFB in France (2017-2030)
Table 20: Microbiology of NCFB patients in France (2017-2030)
Table 21: Prevalent Population of NCFB in Italy (2017-2030)
Table 22: Diagnosed Prevalent Population of NCFB in Italy (2017-2030)
Table 23: Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
Table 24: Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
Table 25: Etiology associated with NCFB in Italy (2017-2030)
Table 26: Microbiology of NCFB patients in Italy (2017-2030)
Table 27: Prevalent Population of NCFB in the Spain (2017-2030)
Table 28: Diagnosed Prevalent Population of NCFB in Spain (2017-2030)
Table 29: Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
Table 30: Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
Table 31: Etiology associated with NCFB in Spain (2017-2030)
Table 32: Microbiology of NCFB patients in Spain (2017-2030)
Table 33: Prevalent Population of NCFB in the UK (2017-2030)
Table 34: Diagnosed Prevalent Population of NCFB in the UK (2017-2030)
Table 35: Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
Table 36: Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
Table 37: Etiology associated with NCFB in the UK (2017-2030)
Table 38: Microbiology of NCFB patients in the UK (2017-2030)
Table 39: Prevalent Population of NCFB in Japan (2017-2030)
Table 40: Diagnosed Prevalent Population of NCFB in Japan (2017-2030)
Table 41: Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
Table 42: Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
Table 43: Etiology associated with NCFB in Japan (2017-2030)
Table 44: Microbiology of NCFB patients in Japan (2017-2030)
Table 45: INS1007, Clinical Trial Description 2020
Table 46: Market size of NCFB in 7MM (2017-2030)
Table 47: The US Market of NCFB in USD Million (2017-2030)
Table 48: The US NCFB Market Size by Therapy in USD Million (2017-2030)
Table 49: The US Market of NCFB in Germany, USD Million (2017-2030)
Table 50: The NCFB Market Size by Therapy in Germany, USD Million (2017-2030)
Table 51: The Market of NCFB in France, USD Million (2017-2030)
Table 52: The NCFB Market Size by Therapy in France, USD Million (2017-2030)
Table 53: The Market of NCFB in Spain, USD Million (2017-2030)
Table 54: The NCFB Market Size by Therapy in Spain, USD Million (2017-2030)
Table 55: The Market of NCFB in Italy, USD Million (2017-2030)
Table 56: The NCFB Market Size by Therapy in Italy, USD Million (2017-2030)
Table 57: The Market of NCFB in UK, USD Million (2017-2030)
Table 58: The NCFB Market Size by Therapy in UK, USD Million (2017-2030)
Table 59: The Market of NCFB in Japan, USD Million (2017-2030)
Table 60: The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)
Table 61: The Market of NCFB in Japan, USD Million (2017-2030)
Table 62: The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)

List of Figures
Figure 1: Common symptoms associated with non-CF bronchiectasis
Figure 2: Morphology of healthy and dilated bronchi
Figure 3: Representation of the cycle that leads to the development of bronchiectasis, as described by Cole
Figure 4: Airway obstruction, impaired mucociliary clearance, and other mechanisms promoting bronchiectasis
Figure 5: Algorithm for the diagnosis and etiologic investigation of bronchiectasis
Figure 6: Algorithm for the therapeutic management of stable bronchiectasis patients
Figure 7: Total Prevalent Population of NCFB in 7 MM (2017-2030)
Figure 8: Prevalent Population of NCFB in the United States (2017-2030)
Figure 9: Diagnosed Population of NCFB in the United States (2017-2030)
Figure 10: Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
Figure 11: Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
Figure 12: Etiology associated with NCFB in the United States (2017-2030)
Figure 13: Microbiology of NCFB patients in the United States (2017-2030)
Figure 14: Prevalent Population of NCFB in Germany (2017-2030)
Figure 15: Diagnosed Population of NCFB in Germany (2017-2030)
Figure 16: Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
Figure 17: Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
Figure 18: Etiology associated with NCFB in the Germany (2017-2030)
Figure 19: Microbiology of NCFB patients in Germany (2017-2030)
Figure 20: Prevalent Population of NCFB in France (2017-2030)
Figure 21: Diagnosed Population of NCFB in France (2017-2030)
Figure 22: Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
Figure 23: Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
Figure 24: Etiology associated with NCFB in France (2017-2030)
Figure 25: Microbiology of NCFB patients in France (2017-2030)
Figure 26: Prevalent Population of NCFB in Italy (2017-2030)
Figure 27: Diagnosed Population of NCFB in Italy (2017-2030)
Figure 28: Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
Figure 29: Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
Figure 30: Etiology associated with NCFB in Italy (2017-2030)
Figure 31: Microbiology of NCFB patients in Italy (2017-2030)
Figure 32: Prevalent Population of NCFB in Spain (2017-2030)
Figure 33: Diagnosed Population of NCFB in Spain (2017-2030)
Figure 34: Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
Figure 35: Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
Figure 36: Etiology associated with NCFB in Spain (2017-2030)
Figure 37: Microbiology of NCFB patients in Spain (2017-2030)
Figure 38: Prevalent Population of NCFB in the UK (2017-2030)
Figure 39: Diagnosed Population of NCFB in the UK (2017-2030)
Figure 40: Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
Figure 41: Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
Figure 42: Etiology associated with NCFB in the UK (2017-2030)
Figure 43: Microbiology of NCFB patients in the UK (2017-2030)
Figure 44: Prevalent Population of NCFB in Japan (2017-2030)
Figure 45: Diagnosed Population of NCFB in Japan (2017-2030)
Figure 46: Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
Figure 47: Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
Figure 48: Etiology associated with NCFB in Japan (2017-2030)
Figure 49: Microbiology of NCFB patients in Japan (2017-2030)
Figure 50: Unmet needs for NCFB
Figure 51: Market Size of NCFB in 7 MM (2017-2030)
Figure 52: Market Size of NCFB in the United States, USD Millions (2017-2030)
Figure 53: The U.S. NCFB Market Size by Therapy USD Million (2017-2030)
Figure 54: Market Size of NCFB in Germany, USD Millions (2017-2030)
Figure 55: The NCFB Market Size by Therapy in Germany, USD Million (2017-2030)
Figure 56: Market Size of NCFB in France, USD Millions (2017-2030)
Figure 57: The NCFB Market Size by Therapy in France, USD Million (2017-2030)
Figure 58: Market Size of NCFB in Spain, USD Millions (2017-2030)
Figure 59: The NCFB Market Size by Therapy in Spain, USD Million (2017-2030)
Figure 60: Market Size of NCFB in Italy, USD Millions (2017-2030)
Figure 61: The NCFB Market Size by Therapy in Italy, USD Million (2017-2030)
Figure 62: Market Size of NCFB in the UK, USD Millions (2017-2030)
Figure 63: The U.S. NCFB Market Size by Therapy in the UK, USD Million (2017-2030)
Figure 64: Market Size of NCFB in Japan, USD Millions (2017-2030)
Figure 65: The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)
Figure 66: Market drivers for NCFB
Figure 67: Market Barriers for NCFB
Note: Product cover images may vary from those shown
3 of 3
  • Aradigm Corporation
  • Zambon
  • Novartis Pharmaceuticals
  • Insmed Incorporated
Note: Product cover images may vary from those shown
Adroll
adroll